drugset / Trial / NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Timeline
- Start
- 2020-03-31
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COM701 | Monoclonal antibody | — | Intravenous |
| Subject | COM902 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |